Pharmacokinetics of indomethacin in the premature infant.
Indomethacin (I) pharmacokinetics was evaluated in 6 premature infants who received the drug for treatment of patent ductus arteriosus. Administered by oral or rectal route, I (0.2 mg/kg/24 h X 3) was promptly absorbed with peak plasma concentrations attained within 1 and 3 h. The elimination of I appeared to follow two compartment open model kinetics, with terminal plasma half-lives ranging from 30 to 90 h. Apparent plasma clearance values were between 0.076 and 0.335 ml/min/kg. Ductal closure was observed in 4 of the 6 infants. Data point to a possible relationship between therapeutic effects and I plasma concentrations.
D003404:Creatinine / Q000097:blood; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy; D005260:Female; D006207:Half-Life; D006801:Humans; D007213:Indomethacin / Q000378:metabolism* / Q000627:therapeutic use; D007231:Infant, Newborn; D007234:Infant, Premature; D007700:Kinetics; D008297:Male; D011453:Prostaglandins / Q000096:biosynthesis
D011453:Prostaglandins; D003404:Creatinine; D007213:Indomethacin